<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2658-6533-2024-10-4-0-7</article-id><article-id pub-id-type="publisher-id">3595</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine (miscellaneous)</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Eating disorders: neuroendocrine changes and potential treatments (review)&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Eating disorders: neuroendocrine changes and potential treatments (review)&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Letyagin</surname><given-names>Pavel I.</given-names></name><name xml:lang="en"><surname>Letyagin</surname><given-names>Pavel I.</given-names></name></name-alternatives><email>letyagin.ps@gmail.com</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Stankevich</surname><given-names>Ludmila N.</given-names></name><name xml:lang="en"><surname>Stankevich</surname><given-names>Ludmila N.</given-names></name></name-alternatives><email>l.stankevich@spbu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ulianova</surname><given-names>Taisiia A.</given-names></name><name xml:lang="en"><surname>Ulianova</surname><given-names>Taisiia A.</given-names></name></name-alternatives><email>taisiia.ulianova@uni-potsdam.de</email></contrib></contrib-group><pub-date pub-type="epub"><year>2024</year></pub-date><volume>10</volume><issue>4</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2024/4/Биомед_исследования-90-100.pdf" /><abstract xml:lang="ru"><p>Background: Eating disorders (EDs) are a group of conditions with an unknown etiology, which is why a comprehensive therapy program is not yet available. The high prevalence and mortality rates underline the interest and necessity of studying this disorder. Recently, accumulating data suggests potential options for hormonal therapy, both conducted on animals and humans. The aim of the study: The exploration of potential hormonal therapy for the treatment of EDs, analysis and synthesis of current approaches to treating hormonal and psychophysiological disturbances in EDs, as well as a review of research conducted on model objects. Materials and methods: In this study a comprehensive literature review to gather relevant articles and research papers was conducted. Various bibliographic databases, including Google Scholar, Web of Science, Scopus and etc. were utilized. The search was performed using a combination of key words related to the topic of EDs: eating disorders, hormonal disturbances in EDs, model organisms for studying EDs, and specific queries related to hormones, receptors, and animal models. Results: Current study presents the main hormonal disturbances involved in the development and maintenance of EDs. Various animal models of EDs are presented, along with the use of agonists of key hormones in animal subjects. Additionally, investigations of the medications relamorelin and metreleptin in humans were also included. Conclusion: The effectiveness of hormonal therapy in humans indicates significant improvement in overall condition within relatively short periods. However, such studies are conducted on insufficient sample sizes for representativeness and require comprehensive double-blind placebo-controlled trials to confirm the efficacy and safety of this therapy</p></abstract><trans-abstract xml:lang="en"><p>Background: Eating disorders (EDs) are a group of conditions with an unknown etiology, which is why a comprehensive therapy program is not yet available. The high prevalence and mortality rates underline the interest and necessity of studying this disorder. Recently, accumulating data suggests potential options for hormonal therapy, both conducted on animals and humans. The aim of the study: The exploration of potential hormonal therapy for the treatment of EDs, analysis and synthesis of current approaches to treating hormonal and psychophysiological disturbances in EDs, as well as a review of research conducted on model objects. Materials and methods: In this study a comprehensive literature review to gather relevant articles and research papers was conducted. Various bibliographic databases, including Google Scholar, Web of Science, Scopus and etc. were utilized. The search was performed using a combination of key words related to the topic of EDs: eating disorders, hormonal disturbances in EDs, model organisms for studying EDs, and specific queries related to hormones, receptors, and animal models. Results: Current study presents the main hormonal disturbances involved in the development and maintenance of EDs. Various animal models of EDs are presented, along with the use of agonists of key hormones in animal subjects. Additionally, investigations of the medications relamorelin and metreleptin in humans were also included. Conclusion: The effectiveness of hormonal therapy in humans indicates significant improvement in overall condition within relatively short periods. However, such studies are conducted on insufficient sample sizes for representativeness and require comprehensive double-blind placebo-controlled trials to confirm the efficacy and safety of this therapy</p></trans-abstract><kwd-group xml:lang="ru"><kwd>eating disorders (EDs)</kwd><kwd>activity-based anorexia (ABA)</kwd><kwd>ghrelin</kwd><kwd>leptin</kwd><kwd>anorexia</kwd></kwd-group><kwd-group xml:lang="en"><kwd>eating disorders (EDs)</kwd><kwd>activity-based anorexia (ABA)</kwd><kwd>ghrelin</kwd><kwd>leptin</kwd><kwd>anorexia</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Schmidt U, Adan R, Bohm I, et al. Eating disorders: the big issue. The Lancet Psychiatry. 2016;3:313-315. DOI: https://doi.org/10.1016/S2215-0366(16)00081-X</mixed-citation></ref><ref id="B2"><mixed-citation>Musatova LA, Krasnova LI, Borisova AM, et al. Features of eating disorders prevalence among adolescents in Penza. University proceedings. Volga region. Medical sciences. 2023;1:49-58. Russian. DOI: https://doi.org/10.21685/2072-3032-2023-1-5</mixed-citation></ref><ref id="B3"><mixed-citation>Arcelus J, Mitchell AJ, Wales J, et al. Mortality rates in patients with anorexia nervosa and other eating disorders a meta-analysis of 36 studies. Archives of General Psychiatry. 2011;68(7):724-731. DOI: https://doi.org/10.1001/archgenpsychiatry.2011.74</mixed-citation></ref><ref id="B4"><mixed-citation>Zakharova LI. Anorexia nervosa: prevalence, diagnostic criteria and psychosomatic relations (review). Research Results in Biomedicine. 2019;5(1):108-121. Russian. DOI: https://doi.org/10.18413/2313-8955-2019-5-1-0-8</mixed-citation></ref><ref id="B5"><mixed-citation>Pursey KM, Hart M, Jenkins L, et al. Screening and identification of disordered eating in people with type 1 diabetes: a systematic review. Journal of Diabetes and its Complications. 2020;34(4):107522. DOI: https://doi.org/10.1016/j.jdiacomp.2020.107522</mixed-citation></ref><ref id="B6"><mixed-citation>Dube MG, Beretta E, Dhillon H, et al. Central leptin gene therapy blocks high fat dietinduced weight gain, hyperleptinemia and hyperinsulinemia: effects on serum ghrelin levels. Diabetes. 2002;51(6):1729-1736. DOI: https://doi.org/10.2337/diabetes.51.6.1729</mixed-citation></ref><ref id="B7"><mixed-citation>Kojima M, Hosoda H, Matsuo H, et al. Ghrelin: a growth hormone-releasing acylated peptide from the stomach. Nature. 1999;402(6762):656-660. DOI: https://doi.org/10.1038/45230</mixed-citation></ref><ref id="B8"><mixed-citation>Rossi E, Cassioli E, Gironi V, et al. Ghrelin as a possible biomarker and maintaining factor in patients with eating disorders reporting childhood traumatic experiences. European Eating Disorders Review. 2021;29(4):588-599. DOI: https://doi.org/10.1002/erv.2831</mixed-citation></ref><ref id="B9"><mixed-citation>Seidel M, Markmann SJ, Healy D, et.al. A Systematic Review and Meta-Analysis Finds Increased Blood Levels of All Forms of Ghrelin in Both Restricting and Binge-Eating/Purging Subtypes of Anorexia Nervosa. Nutrients. 2021;13(2):709. DOI: https://doi.org/10.3390/nu13020709</mixed-citation></ref><ref id="B10"><mixed-citation>M&amp;uuml;ller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Molecular Metabolism. 2015;4(6):437-460. DOI: https://doi.org/10.1016/j.molmet.2015.03.005</mixed-citation></ref><ref id="B11"><mixed-citation>Monteleone AM, Castellini G, Volpe U, et al. Neuroendocrinology and brain imaging of reward in eating disorders: A possible key to the treatment of anorexia nervosa and bulimia nervosa. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018;80(Part B):132-142. DOI: https://doi.org/10.1016/j.pnpbp.2017.02.020</mixed-citation></ref><ref id="B12"><mixed-citation>Blauwhoff-Buskermolen S, Langius JAE, Heijboer AC, et al. Plasma ghrelin levels are associated with anorexia but not cachexia in patients with NSCLC. Frontiers in Physiology. 2017;8:119. DOI: https://doi.org/10.3389/fphys.2017.00119</mixed-citation></ref><ref id="B13"><mixed-citation>Temel JS, Abernethy P, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology. 2016;17(4):519-531. DOI: https://doi.org/10.1016/S1470-2045(15)00558-6</mixed-citation></ref><ref id="B14"><mixed-citation>Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2920-2926. DOI: https://doi.org/10.1210/jc.2004-1788</mixed-citation></ref><ref id="B15"><mixed-citation>Chen CY, Asakawa A, Fujimiya M, et al. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacological Reviews. 2009;61(4):430-481. DOI: https://doi.org/10.1124/pr.109.001958</mixed-citation></ref><ref id="B16"><mixed-citation>Schalla MA, Stengel A. The Role of Ghrelin in Anorexia Nervosa. International Journal of Molecular Sciences. 2018;19(7):2117. DOI: https://doi.org/10.3390/ijms19072117</mixed-citation></ref><ref id="B17"><mixed-citation>Fazeli PK, Lawson EA, Faje AT, et al. Treatment with a ghrelin agonist in outpatient women with anorexia nervosa: A randomized clinical trial. Journal of Clinical Psychiatry. 2018;79(1):1-16.</mixed-citation></ref><ref id="B18"><mixed-citation>Ahmedov VA. Motor disorders of the digestive tract: therapy with prokinetics. Russian Medical Inquiry. 2022;6(5):252-257. Russian. DOI: https://doi.org/10.32364/2587-6821-2022-6-5-252-258</mixed-citation></ref><ref id="B19"><mixed-citation>Hasler WL, Wilson LA, Nguyen LA, et al. Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. Clinical Gastroenterology and Hepatology. 2019;17(7):1285-1294. DOI: https://doi.org/10.1016/j.cgh.2018.10.013</mixed-citation></ref><ref id="B20"><mixed-citation>Smith PM, Brzezinska P, Hubert F, et al. Leptin influences the excitability of area postrema neurons. American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2016;310(5):440-448. DOI: https://doi.org/10.1152/ajpregu.00326.2015</mixed-citation></ref><ref id="B21"><mixed-citation>Friedman JM. Leptin and the endocrine control of energy balance. Nature Metabolism. 2019;1(8):754-764. DOI: https://doi.org/10.1038/s42255-019-0095-y</mixed-citation></ref><ref id="B22"><mixed-citation>Friedman J. The long road to leptin. Journal of Clinical Investigation. 2016;126(12):4727-4734. DOI: https://doi.org/10.1172/JCI91578</mixed-citation></ref><ref id="B23"><mixed-citation>Hebebrand J, Milos G, Wabitsch M, et al. Clinical trials required to assess potential benefits and side effects of treatment of patients with anorexia nervosa with recombinant human leptin. Frontiers in Psychology. 2019;10:769. DOI: https://doi.org/10.3389/fpsyg.2019.00769</mixed-citation></ref><ref id="B24"><mixed-citation>Lee DJ, Elias GJB, Lozano AM. Neuromodulation for the treatment of eating disorders and obesity. Therapeutic Advances in Psychopharmacology. 2018;8(2):73-92. DOI: https://doi.org/10.1177/2045125317743435</mixed-citation></ref><ref id="B25"><mixed-citation>Keel PK, Bodell LP, Haedt-Matt AA, et al. Weight suppression and bulimic syndrome maintenance: Preliminary findings for the mediating role of leptin. International Journal of Eating Disorders. 2017;50(12):1432-1436. DOI: https://doi.org/10.1002/eat.22788</mixed-citation></ref><ref id="B26"><mixed-citation>de Vrind VAJ, Rozeboom A, Wolterink-Donselaar IG, et al. Effects of GABA and Leptin Receptor-Expressing Neurons in the Lateral Hypothalamus on Feeding, Locomotion, and Thermogenesis. Obesity. 2019;27(7):1123-1132. DOI: https://doi.org/10.1002/oby.22495</mixed-citation></ref><ref id="B27"><mixed-citation>Barrios-Correa AA, Estrada JA, Contreras I. Leptin signaling in the control of metabolism and appetite: lessons from animal models. Journal of Molecular Neuroscience. 2018;66:390-402. DOI: https://doi.org/10.1007/s12031-018-1185-0</mixed-citation></ref><ref id="B28"><mixed-citation>Milos G, Antel J, Kaufmann LK, et al. Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Translational Psychiatry. 2020;10(1):303. DOI: https://doi.org/10.1038/s41398-020-00977-1</mixed-citation></ref><ref id="B29"><mixed-citation>Antel J, Tan S, Grabler M, et al. Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism. European Child and Adolescent Psychiatry. 2022;31:1573-1579. DOI: https://doi.org/10.1007/s00787-021-01778-7</mixed-citation></ref><ref id="B30"><mixed-citation>Lutz TA. Control of energy homeostasis by amylin. Cellular and Molecular Life Sciences. 2012;69(12):1947-1965. DOI: https://doi.org/10.1007/s00018-011-0905-1</mixed-citation></ref><ref id="B31"><mixed-citation>Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiology and Behavior. 2010;100(5):511-518. DOI: https://doi.org/10.1016/j.physbeh.2010.03.001</mixed-citation></ref><ref id="B32"><mixed-citation>Keel PK, Haedt-Matt AA, Hildebrandt B, et al. Satiation deficits and binge eating: Probing differences between bulimia nervosa and purging disorder using an ad lib test meal. Appetite. 2018;127:119-125. DOI: https://doi.org/10.1016/j.appet.2018.04.009</mixed-citation></ref><ref id="B33"><mixed-citation>Keel PK, Eckel LA, Hildebrandt BA, et al. Disturbance of gut satiety peptide in purging disorder. International Journal of Eating Disorders. 2018;51(1):53-61. DOI: https://doi.org/10.1002/eat.22806</mixed-citation></ref><ref id="B34"><mixed-citation>Dossat AM, Bodell LP, Williams DL, et al. Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. International Journal of Eating Disorders. 2015;48(2):199-205. DOI: https://doi.org/10.1002/eat.22264</mixed-citation></ref><ref id="B35"><mixed-citation>Duriez P, Ramoz N, Gorwood P, et al. A metabolic perspective on reward abnormalities in anorexia nervosa. Trends in Endocrinology and Metabolism. 2019;30(12):915-928. DOI: https://doi.org/10.1016/j.tem.2019.08.004</mixed-citation></ref><ref id="B36"><mixed-citation>Tyszkiewicz-Nwafor M, Rybakowski F, Dmitzak-Weglarz, et al. Brain-Derived Neurotrophic Factor and Oxytocin Signaling in Association With Clinical Symptoms in Adolescent Inpatients With Anorexia Nervosa - A Longitudinal Study. Frontiers in Psychiatry. 2020;10:1032. DOI: https://doi.org/10.3389/fpsyt.2019.01032</mixed-citation></ref><ref id="B37"><mixed-citation>Mequinion M, Chauveau C, Viltart O. The use of animal models to decipher physiological and neurobiological alterations of anorexia nervosa patients. Frontiers in Endocrinology. 2015:6:68. DOI: https://doi.org/10.3389/fendo.2015.00068</mixed-citation></ref><ref id="B38"><mixed-citation>Scharner S, Stengel A. Animal Models for Anorexia Nervosa - A Systematic Review. Frontiers in Human Neuroscience. 2021;14:596381. DOI: https://doi.org/10.3389/fnhum.2020.596381</mixed-citation></ref><ref id="B39"><mixed-citation>Avraham Y, Bonne O, Berry EM. Behavioral and neurochemical alterations caused by diet restriction - the effect of tyrosine administration in mice. Brain Research. 1996;732(1-2):133-144. DOI: https://doi.org/10.1016/0006-8993(96)00514-8</mixed-citation></ref><ref id="B40"><mixed-citation>Campos GV, de Noronha SR, de Souza AA, et al. Estrogen receptor beta activation within dorsal raphe nucleus reverses anxiety-like behavior induced by food restriction in female rats. Behavioural Brain Research. 2019;357-358:57-64. DOI: https://doi.org/10.1016/j.bbr.2018.03.029</mixed-citation></ref><ref id="B41"><mixed-citation>Avraham Y, Paturski I, Magen I, et al. 2-Arachidonoylglycerol as a possible treatment for anorexia nervosa in animal model in mice. Brain Research. 2017;1670:185-190. DOI: https://doi.org/10.1016/j.brainres.2017.06.003</mixed-citation></ref><ref id="B42"><mixed-citation>Mequinion M, Le Thuc O, Zgheib S, et al. Long-term energy deficit in mice causes long-lasting hypothalamic alterations after recovery. Neuroendocrinology. 2017;105(4):372-383. DOI: https://doi.org/10.1159/000455048</mixed-citation></ref><ref id="B43"><mixed-citation>Mercader JM, Saus E, Aguera Z, et al. Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Human Molecular Genetics. 2008;17(9):1234-1244. DOI: https://doi.org/10.1093/hmg/ddn013</mixed-citation></ref><ref id="B44"><mixed-citation>Kinzig KP, Hargrave SL. Adolescent activity-based anorexia increases anxiety-like behavior in adulthood. Physiology and Behavior. 2010;101(2):269-276. DOI: https://doi.org/10.1016/j.physbeh.2010.05.010</mixed-citation></ref><ref id="B45"><mixed-citation>Aoki C, Sabaliauskas N, Chowdhury T, et al. Adolescent female rats exhibiting activity-based anorexia express elevated levels of GABA A receptor &amp;alpha;4 and &amp;delta; subunits at the plasma membrane of hippocampal CA1 spines. Synapse. 2012;66(5):391-407. DOI: https://doi.org/10.1002/syn.21528</mixed-citation></ref><ref id="B46"><mixed-citation>Wable GS, Barbarich-Marsteller NC, Chowdhury TG, et al. Excitatory synapses on dendritic shafts of the caudal basal amygdala exhibit elevated levels of GABAA receptor &amp;alpha;4 subunits following the induction of activity-based anorexia. Synapse. 2014;68(1):1-15. DOI: https://doi.org/10.1002/syn.21690</mixed-citation></ref><ref id="B47"><mixed-citation>Frintrop L, Liesbrock J, Paulukat L, et al. Reduced astrocyte density underlying brain volume reduction in activity-based anorexia rats. World Journal of Biological Psychiatry. 2018;19(3):225-235. DOI: https://doi.org/10.1080/15622975.2016.1273552</mixed-citation></ref><ref id="B48"><mixed-citation>Frintrop L, Trinh S, Liesbrok J, et al. The reduction of astrocytes and brain volume loss in anorexia nervosa - the impact of starvation and refeeding in a rodent model. Translational Psychiatry. 2019;9(1):159. DOI: https://www.nature.com/articles/s41398-019-0493-7</mixed-citation></ref><ref id="B49"><mixed-citation>Adams KL, Parfeniuk GG, Eikelboom R. Chlorpromazine specifically prevents the wheel-induced feeding suppression in rats. Pharmacology Biochemistry and Behavior. 2009;93(4):470-473. DOI: https://doi.org/10.1016/j.pbb.2009.06.010</mixed-citation></ref><ref id="B50"><mixed-citation>Karth MD, Baugher BJ, Pallechia SA, et al. Brain serotonin deficiency and fluoxetine lead to sex-specific effects on binge-like food consumption in mice. Psychopharmacology. 2022;239(9):2975-2984. DOI: https://doi.org/10.1007/s00213-022-06181-x</mixed-citation></ref><ref id="B51"><mixed-citation>Kooij KL, Luijendijk MCM, Drost L, et al. Intranasal administration of olanzapine has a beneficial outcome in a rat activity-based anorexia model. European Neuropsychopharmacology. 2023;71:65-74. DOI: https://doi.org/10.1016/j.euroneuro.2023.03.008</mixed-citation></ref><ref id="B52"><mixed-citation>Schalla MA, Stengel A. Activity-based anorexia as an animal model for anorexia nervosa &amp;ndash; a systematic review. Frontiers in Nutrition. 2019;6:69. DOI: https://doi.org/10.3389/fnut.2019.00069</mixed-citation></ref><ref id="B53"><mixed-citation>Haines MS. Endocrine complications of anorexia nervosa. Journal of Eating Disorders. 2023;11:24. DOI: https://doi.org/10.1186/s40337-023-00744-9</mixed-citation></ref></ref-list></back></article>